Roche Builds Hematology Pipeline Beyond B-Cell Disease
Roche is not content with replacing its aging Rituxan franchise in blood cancers. At ASCO, the company described its long-term plans to solidify Gazyva as the new CD20 backbone for non-Hodgkin lymphomas while using Venclexta and even newer candidates like targeted therapy idasanutlin to extend into new blood cancer indications – including the high-need acute myeloid leukemia space.
You may also be interested in...
Sales of the psoriasis drug increased 170% in the second quarter to $242m, giving the blood cancer specialist a strong anchor as it looks to expand in inflammation and immunology.
FDA cleared Roche’s Rituxan follow-on GA101 in roughly six months, the same amount of time as an old-school priority review.
FDA reviewers stuck to established assessment practices during the coronavirus crisis and produced one of the agency’s largest yearly novel approval counts ever.